Laura Shawver - May 2, 2022 Form 4 Insider Report for Silverback Therapeutics, Inc. (SPRY)

Role
Chief Executive Officer, Director
Signature
/s/ Jeffrey C. Pepe, Attorney-in-Fact
Stock symbol
SPRY
Transactions as of
May 2, 2022
Transactions value $
$0
Form type
4
Date filed
5/4/2022, 05:19 PM
Previous filing
Feb 2, 2022
Next filing
May 27, 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SPRY Common Stock Award $0 +68.1K +63.42% $0.00 176K May 2, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SPRY Stock Option (right to buy) Award $0 +136K $0.00 136K May 2, 2022 Common Stock 136K $3.15 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares being reported are being issued pursuant to restricted stock units, each one of which represents a contingent right to receive one share of the Issuer's common stock.
F2 The shares subject to the option will vest on May 2, 2023.